Quarterly ResultMay 7, 2026, 04:31 PM
NextCure SIM0505 Receives FDA Fast Track; Q1 Net Loss $9.8M
AI Summary
NextCure announced its first quarter 2026 financial results and provided a business update, highlighted by the FDA granting Fast Track designation for its SIM0505 program for platinum-resistant ovarian cancer. The company reported a net loss of $9.8 million, an improvement from $11.0 million in the prior year. NextCure also initiated dose optimization for SIM0505 and plans to present Phase 1 data at ASCO 2026, while continuing enrollment for its LNCB74 program. The company expects its current financial resources to fund operations into the first half of 2027.
Key Highlights
- SIM0505 received FDA Fast Track designation for platinum-resistant ovarian cancer.
- SIM0505 Phase 1 dose escalation data to be presented at ASCO 2026 on June 1.
- Q1 2026 net loss was $9.8 million, down from $11.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $29.7 million as of March 31, 2026.
- Research and development expenses decreased to $6.8 million from $7.9 million YoY.
- General and administrative expenses decreased to $3.3 million from $3.7 million YoY.
- Current financial resources are expected to fund operations into H1 2027.
Price Impact
More from NXTC